One potential solution to the Trump administration's more assertive posture on pharmaceutical pricing in benchmark countries like Australia is to raise the published list PBS price paid to manufacturers. Yet it could have unintended consequences.
A simple increase in published list prices could have unintended consequences
February 10, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
New Zealand's pre-election Budget boosts health spending, but Pharmac misses out
May 29, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 29 May
May 28, 2026 - - Podcast -
AusBiotech unites conferences under the banner of the 'Biggest Week' in biotech
May 28, 2026 - - Australian Biotech -
Research highlighting gaps leaving some communities at greater risk as flu
May 28, 2026 - - Latest News -
A fraught process but also an opportunity to reintroduce ideas sidelined by the review
May 28, 2026 - - Latest News -
Single infusion of Lilly gene editing cuts cholesterol with the company planning long-term study
May 27, 2026 - - Latest News -
ARCS launches national partnership to boost public clinical research sites
May 27, 2026 - - Latest News
